DEMENTIA

Brand Owner (click to sort) Address Description
DEMENTIA ANSWERS Dementia Society, Inc. P.O. Box 600 Doylestown PA 18901 DEMENTIA;Providing a website featuring a search engine for providing information on dementia, educational information on dementia, and a directory for linking consumers to local, regional and national services relating to dementia;
DEMENTIA DECODER Compassion & Choices 8156 S. Wadsworth Blvd., #E-162 Littleton CO 80128 DEMENTIA;Software as a Service (SaaS) services featuring software for providing information regarding medical conditions, medical treatment options, and medical procedures; Software as a Service (SaaS) services featuring software for helping patients evaluate options and priorities for end-of-life care, helping patients assess benefits and burdens of medical procedures and medical treatment options, and helping patients communicate with medical practitioners;
DEMENTIA SMART Dementia Society, Inc. P.O. Box 600 Doylestown PA 18901 DEMENTIA;Providing a website featuring a search engine for information on dementia, for educational information on dementia, and for local, regional and national services relating to dementia;
THIS IS DEMENTIA DenBoer, John W. 914 W Portland St. Phoenix AZ 85007 A series of books and written articles in the field of dementia;DEMENTIA;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.